Search

Your search keyword '"González Barbera, Eva"' showing total 13 results
Start Over Author "González Barbera, Eva" Publication Year Range Last 50 years
13 results on '"González Barbera, Eva"'

1. Carbapenemase-producing Pseudomonas aeruginosa in Spain: interregional dissemination of the high-risk clones ST175 and ST244 carrying blaVIM-2, blaVIM-1, blaIMP-8, blaVIM-20 and blaKPC-2

Author

PÉREZ-VÁZQUEZ, María, SOLA-CAMPOY, Pedro J., ZURITA, Ángela María, ÁVILA, Alicia, GÓMEZ-BERTOMEU, Frederic, SOLÍS, Sonia, LÓPEZ-URRUTIA, Luis, GÓNZALEZ-BARBERÁ, Eva Mª, CERCENADO, Emilia, BAUTISTA, Verónica, LARA, Noelia, ARACIL, Belén, OLIVER, Antonio, CAMPOS, José, and OTEO-IGLESIAS, Jesús

Published
2020
Full Text
View/download PDF

2. The clinical benefit of instituting a prospective clinical community-acquired respiratory virus surveillance program in allogeneic hematopoietic stem cell transplantation

Author

Piñana, JoséLuis, Montoro, Juan, Aznar, Carla, Lorenzo, Ignacio, Gómez, María Dolores, Guerreiro, Manuel, Carretero, Carlos, González-Barberá, Eva María, Balaguer-Roselló, Aitana, Sanz, Rosa, Salavert, Miguel, Navarro, David, Sanz, Miguel A., Sanz, Guillermo, and Sanz, Jaime

Published
2020
Full Text
View/download PDF

3. Risk factors for mortality among patients with Pseudomonas aeruginosa bacteraemia: a retrospective multicentre study

Author

Babich, Tanya, Naucler, Pontus, Valik, John Karlsson, Giske, Christian G., Benito, Natividad, Cardona, Ruben, Rivera, Alba, Pulcini, Celine, Fattah, Manal Abdel, Haquin, Justine, MacGowan, Alasdair, Grier, Sally, Chazan, Bibiana, Yanovskay, Anna, Ami, Ronen Ben, Landes, Michal, Nesher, Lior, Zaidman-Shimshovitz, Adi, McCarthy, Kate, Paterson, David L., Tacconelli, Evelina, Buhl, Michael, Maurer, Susanna, Rodriguez-Bano, Jesus, Morales, Isabel, Oliver, Antonio, de Gopegui, Enrique Ruiz, Cano, Angela, Machuca, Isabel, Gozalo-Marguello, Monica, Martinez-Martinez, Luis, Gonzalez-Barbera, Eva M., Alfaro, Iris Gomez, Salavert, Miguel, Beovic, Bojana, Saje, Andreja, Mueller-Premru, Manica, Pagani, Leonardo, Vitrat, Virginie, Kofteridis, Diamantis, Zacharioudaki, Maria, Maraki, Sofia, Weissman, Yulia, Paul, Mical, Dickstein, Yaakov, Leibovici, Leonard, and Yahav, Dafna

Published
2020
Full Text
View/download PDF

5. Echinocandins Compared to Fluconazole for Candidemia of a Urinary Tract Source: A Propensity Score Analysis

Author

Grupo de Estudio de Micología Médica (GEMICOMED), Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica (SEIMC), Red Española de Investigación en Patología Infecciosa (REIPI), Cuervo, Guillermo, Garcia-Vidal, Carolina, Puig-Asensio, Mireia, Vena, Antonio, Meije, Yolanda, Fernández-Ruiz, Mario, González-Barberá, Eva, Blanco-Vidal, Maria José, Manzur, Adriana, Cardozo, Celia, Gudiol, Carlota, Montejo, José Miguel, Pemán, Javier, Ayats, Josefina, Aguado, Jose María, Muñoz, Patricia, Marco, Francesc, Almirante, Benito, and Carratalà, Jordi

Published
2017

6. Outcomes of octogenarians and nonagenarians with Pseudomonas aeruginosa bacteremia: a multicenter retrospective study

Author

Atamna, Alaa, Margalit, Ili, Ayada, Gida, Babich, Tanya, Naucler, Pontus, Valik, John Karlsson, Giske, Christian G., Benito, Natividad, Cardona, Rubén, Rivera, Alba, Pulcini, Celine, Fattah, Manal Abdel, Haquin, Justine, Macgowan, Alasdair, Chazan, Bibiana, Yanovskay, Anna, Ami, Ronen Ben, Landes, Michal, Nesher, Lior, Zaidman-Shimshovitz, Adi, McCarthy, Kate, Paterson, David L., Tacconelli, Evelina, Buhl, Michael, Mauer, Susanna, Rodríguez-Baño, Jesús, Cueto, Marina de, Oliver, Antonio, Ruiz-de-Gopegui, Enrique, Cano, Ángela, Machuca, Isabel, Gozalo-Margüello, Mónica, Martínez-Martínez, Luis, González-Barbera, Eva M., Gómez-Alfaro, Iris, Salavert, Miguel, Beovic, Bojana, Saje, Andreja, Mueller-Premru, Manica, Pagani, Leonardo, Vitrat, Virginie, Kofteridis, Diamantis, Zacharioudaki, Maria, Maraki, Sofia, Weissman, Yulia, Paul, Mical, Dickstei, Yaakov, Yahav, Dafna, ESCMID study group for infections in elderly (ESGIE), Atamna, Alaa, Margalit, Ili, Ayada, Gida, Babich, Tanya, Naucler, Pontus, Valik, John Karlsson, Giske, Christian G., Benito, Natividad, Cardona, Rubén, Rivera, Alba, Pulcini, Celine, Fattah, Manal Abdel, Haquin, Justine, Macgowan, Alasdair, Chazan, Bibiana, Yanovskay, Anna, Ami, Ronen Ben, Landes, Michal, Nesher, Lior, Zaidman-Shimshovitz, Adi, McCarthy, Kate, Paterson, David L., Tacconelli, Evelina, Buhl, Michael, Mauer, Susanna, Rodríguez-Baño, Jesús, Cueto, Marina de, Oliver, Antonio, Ruiz-de-Gopegui, Enrique, Cano, Ángela, Machuca, Isabel, Gozalo-Margüello, Mónica, Martínez-Martínez, Luis, González-Barbera, Eva M., Gómez-Alfaro, Iris, Salavert, Miguel, Beovic, Bojana, Saje, Andreja, Mueller-Premru, Manica, Pagani, Leonardo, Vitrat, Virginie, Kofteridis, Diamantis, Zacharioudaki, Maria, Maraki, Sofia, Weissman, Yulia, Paul, Mical, Dickstei, Yaakov, Yahav, Dafna, and ESCMID study group for infections in elderly (ESGIE)

Abstract

[Background] P. aeruginosa bacteremia is a common and severe infection carrying high mortality in older adults. We aimed to evaluate outcomes of P. aeruginosa bacteremia among old adults (≥ 80 years)., [Methods] We included the 464/2394 (19%) older adults from a retrospective multinational (9 countries, 25 centers) cohort study of individuals hospitalized with P. aeruginosa bacteremia. Bivariate and multivariable logistic regression models were used to evaluate risk factors for 30-day mortality among older adults., [Results] Among 464 adults aged ≥ 80 years, the mean age was 84.61 (SD 3.98) years, and 274 (59%) were men. Compared to younger patients, ≥ 80 years adults had lower Charlson score; were less likely to have nosocomial acquisition; and more likely to have urinary source. Thirty-day mortality was 30%, versus 27% among patients 65–79 years (n = 894) and 25% among patients < 65 years (n = 1036). Multivariate analysis for predictors of mortality among patients ≥ 80 years, demonstrated higher SOFA score (odds ratio [OR] 1.36, 95% confidence interval [CI] 1.23–1.51, p < 0.001), corticosteroid therapy (OR 3.15, 95% CI: 1.24–8.01, p = 0.016) and hospital acquired P. aeruginosa bacteremia (OR 2.30, 95% CI: 1.33–3.98, p = 0.003) as predictors. Appropriate empirical therapy within 24 h, type of definitive anti-pseudomonal drug, and type of regimen (monotherapy or combination) were not associated with 30-day mortality., [Conclusions] In older adults with P. aeruginosa bacteremia, background conditions, place of acquisition, and disease severity are associated with mortality, rather than the antimicrobial regimen. In this regard, preventive efforts and early diagnosis before organ failure develops might be beneficial for improving outcomes.

Published
2023

7. Genetic Characterization of Extensively Drug-Resistant Shigella sonnei Infections, Spain, 2021-2022.

Author

Jacqueline, Camille, Ruiz Carrascoso, Guillermo, Gutiérrez-Fernández, José, Vicente Rangel, Teresa, Goterris, Lidia, Vazquez Valdes, Fernando, Fernández Vecilla, Domingo, Elía López, Matilde, Martinez Ruiz, Maria Rocío, Aspiroz Sancho, Carmen, Perez Tanoira, Ramón, Sirvent Quílez, Elia, de la Rica Martínez, Alba, Gonzalo Jiménez, Nieves, García Salguero, Cristina, González Barbera, Eva, Sánchez Florez, Maria Reyes, Merino, Francisco J., Sagardia Redondo, Begoña, and Rodriguez Guerrero, Enrique

Subjects
SHIGELLOSIS, DRUG resistance in microorganisms, DRUG resistance, SHIGELLA
Abstract

In 2022, the United Kingdom reported an increase in drug resistance in Shigella sonnei isolates. We report 33 cases in Spain genetically related to the UK cases and 4 cases with similar antimicrobial resistance profiles infected with genetically distant strains. Our results suggest circulation of multiple genetic clusters of multidrug-resistant S. sonnei in Spain. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

8. Bloodstream Infections in Adult Patients Undergoing Cord Blood Transplantation from Unrelated Donors after Myeloablative Conditioning Regimen

Author

Sanz, Jaime, Cano, Isabel, González-Barberá, Eva M., Arango, Marcos, Reyes, Jheremy, Montesinos, Pau, Lorenzo, Ignacio, Jarque, Isidro, Martínez, Jesús, López, Francisca, Arilla, María J., Lancharro, Aima, Moscardó, Federico, López-Hontangas, José L., Salavert, Miguel, Sanz, Miguel A., and Sanz, Guillermo F.

Published
2015
Full Text
View/download PDF

9. Cytomegalovirus DNAemia in haematological patients undergoing CD19-directed chimeric antigen receptor T-cell therapy: should it be systematically monitored?

Author

Solano de la Asunción, Carlos, Hernani, Rafael, Albert, Eliseo, Gómez, María Dolores, Giménez, Estela, Benzaquén, Ana, González-Barberá, Eva María, Hernández-Boluda, Juan Carlos, Pérez, Ariadna, Piñana, José Luis, Chorao, Pedro, Guerreiro, Manuel, Montoro, Juan, Sanz, Jaime, Solano, Carlos, and Navarro, David

Published
2023
Full Text
View/download PDF

10. Duration of Treatment for Pseudomonas aeruginosa Bacteremia: a Retrospective Study

Author

Yahav, Dafna [0000-0003-3181-9791], Babich, Tanya, Naucler, Pontus, Valik, John Karlsson, Giske, Christian G., Benito, Natividad, Cardona, Rubén, Rivera, Alba, Pulcini, Céline, Fattah, Manal Abdel, Haquin, Justine, Macgowan, Alasdair, Grier, Sally, Chazan, Bibiana, Yanovskay, Anna, Ami, Ronen Ben, Landes, Michal, Nesher, Lior, Zaidman-Shimshovitz, Adi, McCarthy, Kate, Paterson, David L., Tacconelli, Evelina, Buhl, Michael, Mauer, Susanna, Rodríguez-Baño, Jesús, Cueto, Marina de, Oliver, Antonio, Ruiz de Gopegui Bordes, Enrique, Cano, Ángela, Machuca, Isabel, Gozalo-Margüello, Mónica, Martínez-Martínez, Luis, González-Barbera, Eva M., Gómez Alfaro, Iris, Salavert, Miguel, Beovic, Bojana, Saje, Andreja, Mueller-Premru, Manica, Pagani, Leonardo, Vitrat, Virginie, Kofteridis, Diamantis, Zacharioudaki, Maria, Maraki, Sofia, Weissman, Yulia, Paul, Mical, Dickstein, Yaakov, Leibovici, Leonard, Yahav, Dafna, Yahav, Dafna [0000-0003-3181-9791], Babich, Tanya, Naucler, Pontus, Valik, John Karlsson, Giske, Christian G., Benito, Natividad, Cardona, Rubén, Rivera, Alba, Pulcini, Céline, Fattah, Manal Abdel, Haquin, Justine, Macgowan, Alasdair, Grier, Sally, Chazan, Bibiana, Yanovskay, Anna, Ami, Ronen Ben, Landes, Michal, Nesher, Lior, Zaidman-Shimshovitz, Adi, McCarthy, Kate, Paterson, David L., Tacconelli, Evelina, Buhl, Michael, Mauer, Susanna, Rodríguez-Baño, Jesús, Cueto, Marina de, Oliver, Antonio, Ruiz de Gopegui Bordes, Enrique, Cano, Ángela, Machuca, Isabel, Gozalo-Margüello, Mónica, Martínez-Martínez, Luis, González-Barbera, Eva M., Gómez Alfaro, Iris, Salavert, Miguel, Beovic, Bojana, Saje, Andreja, Mueller-Premru, Manica, Pagani, Leonardo, Vitrat, Virginie, Kofteridis, Diamantis, Zacharioudaki, Maria, Maraki, Sofia, Weissman, Yulia, Paul, Mical, Dickstein, Yaakov, Leibovici, Leonard, and Yahav, Dafna

Abstract

[Introduction] There is no consensus regarding optimal duration of antibiotic therapy for Pseudomonas aeruginosa bacteremia. We aimed to evaluate the impact of short antibiotic course., [Methods] We present a retrospective multicenter study including patients with P. aeruginosa bacteremia during 2009–2015. We evaluated outcomes of patients treated with short (6–10 days) versus long (11–15 days) antibiotic courses. The primary outcome was a composite of 30-day mortality or bacteremia recurrence and/or persistence. Univariate and inverse probability treatment-weighted (IPTW) adjusted multivariate analysis for the primary outcome was performed. To avoid immortal time bias, the landmark method was used., [Results] We included 657 patients; 273 received a short antibiotic course and 384 a long course. There was no significant difference in baseline characteristics of patients. The composite primary outcome occurred in 61/384 patients in the long-treatment group (16%) versus 32/273 in the short-treatment group (12%) (p = 0.131). Mortality accounted for 41/384 (11%) versus 25/273 (9%) of cases, respectively. Length of hospital stay was significantly shorter in the short group [median 13 days, interquartile range (IQR) 9–21 days, versus median 15 days, IQR 11–26 days, p = 0.002]. Ten patients in the long group discontinued antibiotic therapy owing to adverse events, compared with none in the short group. On univariate and multivariate analyses, duration of therapy was not associated with the primary outcome., [Conclusions] In this retrospective study, 6–10 days of antibiotic course for P. aeruginosa bacteremia were as effective as longer courses in terms of survival and recurrence. Shorter therapy was associated with reduced length of stay and less drug discontinuation.

Published
2022

13. Adoptive transfer of ex vivo expanded SARS‐CoV‐2‐specific cytotoxic lymphocytes: A viable strategy for COVID‐19 immunosuppressed patients?

Author

Generalitat Valenciana, Consejo Superior de Investigaciones Científicas (España), Aguilar-Gallardo, Cristóbal [0000-0002-1594-3648], Piñana, José Luis [0000-0001-8533-2562], Guerreiro, Manuel, Aguilar-Gallardo, Cristóbal, Montoro, Juan, Francés-Gómez, Clara, Latorre, Victor, Luna, Irene, Planelles, Dolores, Carrasco, María Paz, Gómez, María Dolores, González-Barbera, Eva M., Aguado, Cristina, Sempere, Amparo, Solves, Pilar, Gómez-Seguí, Inés, Balaguer-Rosello, Aitana, Louro, Alberto, Perla, Aurora, Larrea, Luis, Sanz, Jaime, Arbona, Cristina, Rubia, Javier de la, Geller, Ron, Sanz, Miguel Ángel, Sanz, Guillermo, Piñana, José Luis, Generalitat Valenciana, Consejo Superior de Investigaciones Científicas (España), Aguilar-Gallardo, Cristóbal [0000-0002-1594-3648], Piñana, José Luis [0000-0001-8533-2562], Guerreiro, Manuel, Aguilar-Gallardo, Cristóbal, Montoro, Juan, Francés-Gómez, Clara, Latorre, Victor, Luna, Irene, Planelles, Dolores, Carrasco, María Paz, Gómez, María Dolores, González-Barbera, Eva M., Aguado, Cristina, Sempere, Amparo, Solves, Pilar, Gómez-Seguí, Inés, Balaguer-Rosello, Aitana, Louro, Alberto, Perla, Aurora, Larrea, Luis, Sanz, Jaime, Arbona, Cristina, Rubia, Javier de la, Geller, Ron, Sanz, Miguel Ángel, Sanz, Guillermo, and Piñana, José Luis

Abstract

Cellular and humoral response to acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infections is on focus of research. We evaluate herein the feasibility of expanding virus‐specific T cells (VST) against SARS‐CoV‐2 ex vivo through a standard protocol proven effective for other viruses. The experiment was performed in three different donors' scenarios: (a) SARS‐CoV‐2 asymptomatic infection/negative serology, (b) SARS‐CoV‐2 symptomatic infection/positive serology, and (c) no history of SARS‐CoV‐2 infection/negative serology. We were able to obtain an expanded VST product from donors 1 and 2 (1.6x and 1.8x increase of baseline VST count, respectively) consisting in CD3 + cells (80.3% and 62.7%, respectively) with CD4 + dominance (60% in both donors). Higher numbers of VST were obtained from the donor 2 as compared to donor 1. T‐cell clonality test showed oligoclonal reproducible peaks on a polyclonal background for both donors. In contrast, VST could be neither expanded nor primed in a donor without evidence of prior infection. This proof‐of‐concept study supports the feasibility of expanding ex vivo SARS‐CoV‐2‐specific VST from blood of convalescent donors. The results raise the question of whether the selection of seropositive donors may be a strategy to obtain cell lines enriched in their SARS‐CoV‐2‐specificity for future adoptive transfer to immunosuppressed patients.

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results